What we know: Findings that every theory of Schizophrenia should explain

Schizophrenia Bulletin

Volumn 35, Issue 3, 2009, Pages 493-508

  MacDonald, Angus W ^a   Schulz, S Charles ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Meta analysis; Review; Schizophrenia; Theory

Indexed keywords

ACETYLCYSTEINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE;

CHROMOSOME; GENETIC ASSOCIATION; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; SUICIDAL BEHAVIOR; THEORY CONSTRUCTION;

ANTIPSYCHOTIC AGENTS; BRAIN; CHROMOSOME MAPPING; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; ODDS RATIO; RECEPTORS, DOPAMINE D2; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX RATIO;

EID: 65349088024     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbp017     Document Type: Review

References (115)

1. Peralta V, Cuesta MJ. How many and which are the psychopathological dimensions of schizophrenia? Issues influencing their ascertainment. Schizophr Res. 2001;49:269-285.
2. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2:413-433.
3. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003;60:565-571.
4. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000;401:3-38.
5. Howard R, Rabins PV, Seeman MV, Jeste DV. Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia Group. Am J Psychiatry. 2000;157(2): 172-178.
6. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60:1187-1192.
7. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry. 2003;160:636-645.
8. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50:873-883.
9. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
10. Owen MJ, Craddock N, O'Donovan MC. Schizophrenia: genes at last? Trends Genet. 2005;21:518-525.
11. Snitz BE, Macdonald AW, III, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2006;32(1):179-194.
12. Boos HB, Aleman A, Cahn W, Pol HH, Kahn RS. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Arch Gen Psychiatry. 2007;64:297-304.
13. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2:13.
14. Zammit S, Allebeck P, Dalman C, et al. Paternal age and risk for schizophrenia. Br J Psychiatry. 2003;183:405-408.
15. Torrey EF, Bartko JJ, Lun Z, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull. 2007;33:729-736.
16. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31:608-612.
17. Krabbendam L, van Os J. Schiziophrenia and urbanicity: a major environmental influence - conditional on genetic risk. Schizophr Bull. 2005;31:795-799.
18. Davies G, Welham J, Chant D, Torrey EF, McGrath J. A systematic review and meta-analysis of northern hemisphere season of birth studies in schizophrenia. Schizophr Bull. 2003;29:587-593.
19. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60(12):1228-1235.
20. Emsley R, Rabinowitz J, Medori R. Time course for anti-psychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006;163:743-745.
21. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr Bull. 1990;16(1):97-110.
22. Segal DS, Kuczenski R. An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci. 1997;17:2551-2566.
23. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308.
24. Pfammatter M, Junghan UM, Brenner HD. Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. Schizophr Bull. 2006;32(suppl 1):S64-S80.
25. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785-1804.
26. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62:247-253.
27. Heinrichs RW. In Search of Madness: Schizophrenia and Neuroscience. Oxford: Oxford University Press; 2001.
28. Heinrichs RW. The primacy of cognition in schizophrenia. Am Psychol. 2005;60:229-242.
29. Lewis DA, Glantz LA, Pierri JN, Sweet RA. Altered cortical glutamate neurotransmission in schizophrenia: evidence from morphological studies of pyramidal neurons. Ann N Y Acad Sci. 2003;1003:102-112.
30. Akbarian S, Huang HS. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev. 2006;52:293-304.
31. Vita A, De Peri L, Silenzi C, Dieci M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr Res. 2006; 82(1):75-88.
32. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry. 2006;188:510-518.
33. Davidson LL, Heinrichs RW. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res. 2003;122(2):69-87.
34. Konick LC, Friedman L. Meta-analysis of thalamic size in schizophrenia. Biol Psychiatry. 2001;49(1):28-38.
35. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res. 2005;76(1):1-23.
36. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res. 2004;70:315-329.
37. Van Snellenberg JX, Torres IJ, Thornton AE. Functional neuroimaging of working memory in schizophrenia: task performance as a moderating variable. Neuropsychology. 2006;20:497-510.
38. Glahn DC, Ragland JD, Abramoff A, et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Mapp. 2005;25(1):60-69.
39. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426-445.
40. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007;64:532-542.
41. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72(1):41-51.
42. Carpenter WT, Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145:578-583.
43. Gottesman II, Shields J. Schizophrenia: The Epigenetic Puzzle. New York: Cambridge University Press; 1982.
44. Crow TJ. Molecular pathology of schizophrenia: More than one dimension of pathology? Br Med J. 1980;280:66-68.
45. Cohen E, Chow EWC, Weksberg R, Bassett AS. Phenotype of adults with the 22q11 deletion syndrome: a review. Am J Med Genet. 1999;86:359-365.
46. Andreasen NC, Nopoulos P, Schultz S, et al. Positive and negative symptoms of schizophrenia: past, present, and future. Acta Psychiatr Scand Suppl. 1994;384:51-59.
47. Owen MJ, Craddock N, Jablensky A. The genetic deconstruction of psychosis. Schizophr Bull. 2007;33:905-911.
48. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the COMT gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;15:1117-1127.
49. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001; 98:6917-6922.
50. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl. 1992;20:1-97.
51. Hafner H, Maurer K, Loffler W, An Der Heiden W, Munk-Jorgensen P, Hambrecht M. The ABC schizophrenia study: a preliminary overview of the results. Soc Psychiatry Psychiatr Epidemiol. 1998;33:380-386.
52. Loranger AW. Sex differences in age at onset of schizophrenia. Arch Gen Psychiatry. 1984;41:157-161.
53. Cannon TD, Kaprio J, Lonnqvist J, Huttunen M, Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort: a population based model and study. Arch Gen Psychiatry. 1998;55:67-64.
54. Lichtenstein P, BHY, Bjork C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet. 2009;373:234-239.
55. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 1963;20:140-144.
56. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481-483.
57. Kane J, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45: 789-796.
58. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med. 2007;13:1102-1107.
59. Lewis CM, Levinson DI, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet. 2003;73(1):34.
60. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002;7(4):405.
61. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40: 827-834.
62. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320:539-543.
63. Consortium IS. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455:237-241.
64. Smitha R, Sutrala SR, Norton N, Williams NM, Buckland PR. Gene copy number variation in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:606-611.
65. Snitz BE, MacDonald AW, III, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull. 2006;32(1):179-194.
66. MacDonald AW, III, Thermenos HW, Barch DM, Seidman LJ. Imaging genetic liability to schizophrenia: systematic review of fMRI studies of patients' nonpsychotic relatives. Schizophr Bull. 2008. doi:10.1093/schbul/sbp053.
67. Boos HB, Aleman A, Cahn W, Pol HH, Kahn RS. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Arch Gen Psychiatry. 2007;64:297-304.
68. Pogue-Geile MF, Gottesman II. Schizophrenia: study of a genetically complex phenotype. In: Jones BC, Mormede P, eds. Neurobehavioral Genetics: Methods and Applications. Boca Raton, FL: CRC Press; 1999:247-264.
69. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102:230-240.
70. Angrist B, Gershon S. Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects. Adv Biochem Psychopharmacol. 1977;16:677-680.
71. Laruelle M, Abi-Dargham A, Gil R, Kegeles LS, Innis RB. Increased dopamince transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46(1):56-72.
72. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997;94:2569-2574.
73. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A. 1996;93:9235-9240.
74. Schulz SC, Cornelius J, Schulz PM, Soloff PH. The amphetamine challenge test in patients with borderline disorder. Am J Psychiatry. 1988;145:809-814.
75. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148: 1301-1308.
76. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 1995;6:869-872.
77. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64: 361-368.
78. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34:523-537.
79. Bellack AS. Cognitive rehabiliation for schizophrenia: is it possible? Is it necessary? Schizophr Bull. 1992;18:43-50.
80. Medalia A, Aluma M, Tyron W, Merriam AE. Effectiveness of attention training in schizophrenia. Schizophr Bull. 1998;24(1):147-152.
81. Velligan DI, Prihoda TJ, Ritch JL, Maples N, Bow-Thomas CC, Dassori A. A randomized single-blind pilot study of compensatory strategies in schizophrenia outpatients. Schizophr Bull. 2002;28:283-292.
82. Hogarty GE, Anderson CM, Reiss DJ, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion. Arch Gen Psychiatry. 1986;43:633-642.
83. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986;148:120-127.
84. May PR, Tuma AH, Yale C, Potepan P, Dixon WJ. Schizophrenia - a follow-up study of results of treatment. Arch Gen Psychiatry. 1976;33:481-486.
85. Melle I, Larsen TK, Haahr U, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch Gen Psychiatry. 2008;65:634-640.
86. Westermeyer JF, Harrow M, Marengo JT. Risk for suicide in schizophrenia and other psychotic and nonpsychotic disorders. J Nerv Ment Dis. 1991;179:259-266.
87. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1): 82-91.
88. Todtenkopf MS, Vincent SL, Benes FM. A cross-study meta-analysis and three-dimensional comparison of cell counting in the anterior cingulate cortex of schizophrenic and bipolar brain. Schizophr Res. 2005;73:79-89.
89. Selemon L, Mrzljak J, Kleinman J, Herman M, Goldman-Rakic P. Regional specificity in the neuropathologic substrates of schizophrenia: a morphometric analysis of Broca's Area 44 and Area 9. Arch Gen Psychiatry. 2003;60:69-77.
90. Heinrichs RW. The primacy of cognition in schizophrenia. Am Psychol. 2005;60:229-242.
91. de Haan M, Wyatt JS, Roth S, Vargha-Khadem F, Gadian D, Mishkin M. Brain and cognitive-behavioural development after asphyxia at term birth. Dev Sci. 2006;9:350-358.
92. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005;6:312-324.
93. Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci. 2007;104:10164-10169.
94. Weinberger DR, Torrey EF, Neophytides AN, Wyatt RJ. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry. 1979;36:735-739.
95. Nasrallah HA, Olson SC, McCalley-Whitters M, Chapman S, Jacoby CG. Cerebral ventricular enlargement in schizophrenia. A preliminary follow-up study. Arch Gen Psychiatry. 1986;43(2):157-159.
96. Elkis H, Friedman L, Wise A, Meltzer HY. Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. Arch Gen Psychiatry. 1995;52: 735-746.
97. Degreef G, Ashtari M, Bogerts B, et al. Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Arch Gen Psychiatry. 1992;49:531-537.
98. DeLisi LE, Tew W, Xie S, et al. A prospective follow-up study of brain morphology and cognition in first-episode schizophrenic patients: preliminary findings. Biol Psychiatry. 1995;38:349-360.
99. Rapoport JL, Giedd J, Kumra S, et al. Childhood-onset schizophrenia. Progressive ventricular change during adolescence. Arch Gen Psychiatry. 1997;54:897-903.
100. Ward KE, Friedman L, Wise A, Schulz SC. Meta-analysis of brain and cranial size in schizophrenia. Schizophr Res. 1996; 22(3):197-213.
101. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry. 2003;60:585-594.
102. Cahn W, Hulshoff Pol HE, Lems EB, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry. Nov 2002;59(11):1002-1010.
103. Goldstein JM, Goodman JM, Seidman LJ, et al. Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging. Arch Gen Psychiatry. 1999;56: 537-547.
104. Kuperberg GR, Broome MR, McGuire PK, et al. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry. 2003;60:878-888.
105. Andreasen NC, Arndt S, Swayze VN, et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science. 1994;266:294-298.
106. Davidson LL, Heinrichs RW. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res. 2003;122:69-87.
107. Kraepelin E. Clinical Psychiatry: A Textbook for Students and Physicians. 7th ed. London: MacMillan Company; 1907.
108. Ingvar DH, Franzen G. Distribution of cerebral activity in chronic schizophrenia. Lancet. 1974;1484-1486.
109. Glahn DC, Ragland JD, Adramoff A, et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Mapp. 2005;25:60-69.
110. Bleuler E. Dementia Praecox or the Group of Schizophrenias. New York: International Universities Press (Original work published 1911); 1950.
111. Chapman LJ, Chapman JP. Disordered Thought in Schizophrenia. Englewood Cliffs, NJ: Prentice-Hall, Inc.; 1973.
112. Wexler BE, Bell MD. Cognitive remediation and vocational rehabilitation for schizoiphrenia. Schizophr Bull. 2005;31:931-941.
113. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "Just the Facts": what we know in 2008 Part 1: overview. Schizophr Res. 2008;100(4):4-19.
114. MacDonald AW, III, Tandon R, Nasrallah HA, Schulz SC, Kapur S. Body of Knowledge: The Purposes, Approaches and Outcome of Appraising What We Know About Schizophrenia. San Diego, CA: International Congress of Schizophrenia Research; 2009.
115. St Clair D, Xu M, Wang P, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA. 2005;294(5):557-562.